

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1626

BOLD, Guido et al.

Examiner: SHAMEEM, Golam M.

INTERNATIONAL APPLICATION NO: PCT/EP2004/012892

FILED: 12 November 2004

U.S. APPLICATION NO: 10/578,826

35 USC §371 DATE: 20 November 2006

FOR: Thiazole and Pyrazole Derivatives as FLT-3 Kinase Inhibitors

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO ELECTION/RESTRICTION

Sir:

In response to the Restriction Requirement mailed on 15 June 2009, a response to which is due 15 November 2009 with the enclosed four month extension of time fee, Applicants elect to prosecute claims of group I without traverse. Applicants further elect the species of Example 5, namely [5-(4-Methoxy-phenyl)-thiazol-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine, for prosecution.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,


Mark E. Baron
Attorney for Applicants
Reg. No. 46,150

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-7347

Date: 13 November 2009